Oxford - Oxford Biomedica plc , a quality and innovation-led cell and gene therapy CDMO, and Institut Merieux SA today announce that they have entered into exclusive negotiations with respect to the.
Oxford BioMedica PLC on Wednesday said loss widened in the first half of 2023 as revenue fell, while it noted being in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15.
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation No. 596/2014 Act 2018). Upon the.